Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Onyx Pharmaceuticals Announces First Quarter 2011 Financial Results Teleconference and Webcast

April 21, 2011

SAN FRANCISCO, April 21, 2011 /PRNewswire/ — Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to discuss first quarter 2011 financial results, as well as provide a general business overview on Wednesday, May 4, 2011, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time; 2:00 p.m. Central European Time). Financial results for the first quarter ended March 31, 2011 will be released earlier that day.

Interested parties may access a live webcast of the presentation on the company’s website at: http://www.onyx-pharm.com/investors/event-calendar


    Within the
     U.S.:          888-771-4371
    International:  847-585-4405
    Passcode:       29609004#

    A replay of the presentation will be available on the Onyx website or
     by dialing:

    Dial in:        630-652-3042
                     29609004# (approximately one hour after the
    Passcode:        teleconference concludes)

    The replay will be available through May 18, 2011.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma in various settings and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company’s website at www.onyx-pharm.com.

SOURCE Onyx Pharmaceuticals, Inc.


Source: newswire